Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy

Journal of Clinical Investigation

Volumn 106, Issue 1, 2000, Pages 117-124

  Fehniger, Todd A ^a,b,d   Bluman, Eric M ^b   Porter, Michelle M ^b   Mrózek, Ewa ^b   Cooper, Megan A ^a   VanDeusen, Jeffrey B ^a   Frankel, Stanley R ^b   Stock, Wendy ^c   Caligiuri, Michael A ^a,b,d  

^a Division of Hematology/Oncology   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; LEUKOCYTE COUNT; LEUKOPOIESIS; NATURAL KILLER CELL; PRIORITY JOURNAL;

EID: 0033945954     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6218     Document Type: Article

References (29)

1. Robertson, M.J., and Ritz, J. 1990. Biology and clinical relevance of human natural killer cells. Blood. 76:2421-2438.
2. Caligiuri, M.A., et al. 1990. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. 171:1509-1526.
3. Nagler, A., Lanier, L.L., and Phillips, J.H. 1990. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J. Exp. Med. 171:1527-1533.
4. Caligiuri, M.A., et al. 1993. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. 91:123-132.
5. Frankel, S.R., et al. 1994. Low dose interleukin-2 (IL-2) as post remission therapy for AML increases NK cell populations. Proceedings of the American Association for Cancer Research. 35:225. (Abstr.)
6. Bernstein, Z.P., et al. 1995. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood. 86:3287-3294.
7. Meropol, N.J., et al. 1996. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin. Cancer Res. 2:669-677.
8. Bernstein, Z.P., et al. 1998. A phase I/II study of daily subcutaneous low dose interleukin-2 in AIDS-associated lymphomas. Blood. 92:625a. (Abstr.)
9. Khatri, V.P., et al. 1998. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J. Clin. Invest. 101:1373-1378.
10. Baer, M.R., et al. 1993. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Semin. Oncol. 20:6-12.
11. Matos, M.E., et al. 1993. Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp. Med. 178:1079-1084.
12. Carson, W.E., et al. 1994. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180:1395-1403.
13. Rabinovitch, P.S., Kubbies, M., Chen, Y.C., Schindler, D., and Hoehn, H. 1988. BrdU-Hoechst flow cytometry: a unique tool for quantitative cell cycle analysis. Exp. Cell Res. 174:309-318.
14. Baiocchi, R.A., et al. 1995. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood. 85:1063-1074.
15. Nicoletti, I., Migliorati, G., Pagliacci, M.C., Grignani, F., and Riccardi, C. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:271-279.
16. Renno, T., Hahne, M., and MacDonald, H.R. 1995. Proliferation is a prerequisite for bacterial superantigen-induced T cell apoptosis in vivo. J. Exp. Med. 181:2283-2287.
17. Mrozek, E., Anderson, P., and Caligiuri, M.A. 1996. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 87:2632-2640.
18. Langley, K.E., et al. 1993. Soluble stem cell factor in human serum. Blood. 81:656-660.
19. Penninger, J.M., and Mak, T.W. 1994. Signal transduction, mitotic catastrophes, and death in T-cell development. Immunol. Rev. 142:231-272.
20. Lotzova, E., Savary, C.A., and Champlin, R.E. 1993. Genesis of human oncolytic natural killer cells from primitive CD34+CD33-bone marrow progenitors. J. Immunol 150:5263-5269.
21. Miller, J.S., Verfaillie, C., and McGlave, P. 1992. The generation of human natural killer cells from CD34+/DR-primitive progenitors in long-term bone marrow culture. Blood. 80:2182-2187.
22. Miller, J.S., Alley, K.A., and McGlave, P. 1994. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. Blood. 83:2594-2601.
23. Shibuya, A., Nagayoshi, K., Nakamura, K., and Nakauchi, H. 1995. Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 85:3538-3546.
24. Yu, H., et al. 1998. Flt3 ligand promotes the generation of a distinct CD34+ human natural killer cell progenitor that responds to interleukin-15. Blood. 92:3647-3657.
25. Fehniger, T.A., Carson, W.E., Mrozek, E., and Caligiuri, M.A. 1997. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo. Blood. 90:3647-3653.
26. Silva, M.R., Hoffman, R., Srour, E.F., and Ascensao, J.L. 1994. Generation of human natural killer cells from immature progenitors does not require marrow stromal cells. Blood. 84:841-846.
27. Krajewski, C.A., Mrozek, E., and Caligiuri, M.A. 1994. Generation and expansion of CD3-CD56+ non-MHC-restricted cytotoxic effectors from human hematopoietic precursors; requirement for c-kit ligand and interleukin-2. Proceedings of the American Society for Clinical Oncology. 13:294. (Abstr.)
28. Dale, D.C., Liles, W.C., Summer, W.R., and Nelson, S. 1995. Review: granulocyte colony-stimulating factor: role and relationships in infectious diseases. J. Infect. Dis. 172:1061-1075.
29. Nishikawa, K., et al. 1991. Accumulation CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua. Int. Immunol. 3:743-750.